Trigeminal Nerve Stimulation in Treatment-resistant Generalized Anxiety Disorder: a Feasibility Study (NCT06278909)
🩺 Plain-English Summary (8th-Grade Level)
This is a feasibility study for trigeminal nerve stimulation (TNS) in patients with treatment-resistant generalized anxiety disorder (TR-GAD). Ten participants will receive TNS for 8 weeks as an augmentation strategy to pharmacological treatment for generalized anxiety disorder (GAD). * The primary objective is to ascertain if TNS is a safe and well-tolerated treatment for patients with TR-GAD. * The secondary objective will be to monitor changes in GAD symptom severity throughout the study. Results from this study will inform a randomized controlled trial to be conducted in the future.
Who can join: Review the eligibility criteria below.
Location: Kingston Health Sciences Centre — Kingston, Ontario
Age range: 18 Years to 65 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- Kingston Health Sciences Centre — Kingston, Ontario
📞 Contact the Study Coordinator
Phone: (613) 548-7839
Email: yan.deng@queensu.ca
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Generalized Anxiety Disorder
- A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama) — Little Rock, Arkansas
- A Phase 3 Trial of DT120 for Generalized Anxiety Disorder (Voyage) — Gilbert, Arizona
- MBSR Mechanisms in GAD — New York, New York
- Efficacy and Safety of Inhaled NC-107 As Compared to Placebo After 4 Weeks of Treatment in Patients with Anxiety — Carrollton, Texas
- Understanding of Participation Trends Within Generalized Anxiety Disorder Patients Involved in Clinical Trials — San Francisco, California
- Adjunctive Treatment With L-methylfolate for Treatment-Resistant Generalized Anxiety Disorder: a Pilot Study — Kingston, Ontario
Explore by condition: All Generalized Anxiety Disorder clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.